Citius Pharmaceuticals, Inc. (CTXR) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.08
↓-96% vs avg
5yr avg: 1.93
30Y Low0.2·High3.4
ROE
↓
-49.4%
↑-32% vs avg
5yr avg: -37.3%
30Y Low-103%·High-28%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.0·High0.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CTXR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Citius Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6M | $14M | $145M | $173M | $295M | $367M | $68M | $25M | $31M | $29M | $57M |
| Enterprise Value | $4M | $11M | $142M | $147M | $254M | $298M | $55M | $18M | $22M | $26M | $57M |
| P/E Ratio → | -0.17 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.08 | 0.18 | 1.96 | 1.89 | 2.85 | 2.77 | 2.02 | 1.04 | 1.10 | 1.31 | 3.40 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CTXR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
CTXR Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -49.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -49.4% | -49.4% | -47.3% | -33.4% | -28.5% | -27.8% | -60.5% | -59.6% | -50.3% | -53.6% | -102.9% |
| ROA | -30.2% | -30.2% | -35.5% | -29.9% | -26.2% | -24.8% | -48.2% | -51.9% | -45.2% | -44.8% | -73.1% |
| ROIC | -39.5% | -39.5% | -46.1% | -43.1% | -39.7% | -41.7% | -70.2% | -65.9% | -54.8% | -41.5% | -70.6% |
| ROCE | -46.2% | -46.2% | -47.0% | -35.4% | -26.9% | -26.4% | -55.3% | -59.7% | -55.4% | -51.6% | -92.4% |
CTXR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $4M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.00 | 0.01 | 0.01 | 0.01 | 0.04 | 0.01 | 0.01 | 0.01 | 0.04 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.03 | -0.04 | -0.28 | -0.40 | -0.52 | -0.37 | -0.32 | -0.32 | -0.14 | 0.02 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -143.46 | -143.46 | — | — | -131.52 | -2125.99 | -1118.64 | -945.43 | -790.55 | -11.74 | -828.25 |
Net cash position: cash ($4M) exceeds total debt ($2M)
CTXR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.62x is below 1.0, meaning current liabilities exceed current assets. The quick ratio of 0.13x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 5.95x to 0.62x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.62 | 0.62 | 0.40 | 5.95 | 9.84 | 18.28 | 3.41 | 1.72 | 3.16 | 1.39 | 0.17 |
| Quick Ratio | 0.13 | 0.13 | 0.17 | 5.95 | 9.84 | 18.28 | 3.41 | 1.72 | 3.16 | 1.39 | 0.17 |
| Cash Ratio | 0.09 | 0.09 | 0.09 | 4.58 | 9.21 | 17.60 | 3.38 | 1.71 | 2.88 | 1.30 | 0.06 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | 0.01 | 0.01 | 0.03 | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
CTXR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Citius Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $11M | $12M | $10M | $10M | $7M | $3M | $1M | $715458 | $365500 | $241547 |
Peer Comparison
Compare CTXR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CTXRYou | $6M | -0.2 | — | — | — | — | -49.4% | -39.5% | — |
 NKTR | $1B | -6.8 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 HALO | $8B | 26.9 | 11.3 | 12.7 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
 PRGO | $1B | -0.9 | 7.0 | 9.2 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 PAHC | $1B | 26.1 | 12.5 | 30.1 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 ETON | $896M | -192.5 | 219.0 | 87.9 | 53.5% | 0.1% | -18.2% | 0.2% | 7.5 |
 TLRY | $535M | -0.1 | — | — | 29.3% | -277.9% | -89.1% | -66.2% | — |
 MNKD | $1B | 194.5 | 31.3 | 87.8 | 82.5% | 11.1% | — | 21.6% | 9.3 |
 ACRS | $584M | -9.1 | — | — | 73.3% | -975.9% | -50.2% | -53.0% | — |
 PHAT | $849M | -3.5 | — | — | 87.1% | -91.4% | — | — | — |
 MCK | $90B | 19.4 | 13.1 | 15.7 | 3.6% | 1.6% | — | 254.1% | 1.2 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
CTXR — Frequently Asked Questions
Quick answers to the most common questions about buying CTXR stock.
What is Citius Pharmaceuticals, Inc.'s P/E ratio?
Citius Pharmaceuticals, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
What is Citius Pharmaceuticals, Inc.'s ROE?
Citius Pharmaceuticals, Inc.'s return on equity (ROE) is -49.4%. The historical average is -51.3%.
Is CTXR stock overvalued?
Based on historical data, Citius Pharmaceuticals, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.